Bill > SB01421

This bill aims to improve access to more affordable obesity and diabetes medications for Connecticut's HUSKY Health program members by establishing a process to pursue generic alternatives to brand-name drugs. Specifically, the Commissioner of Social Services is required to petition the federal government within 30 days to authorize generic versions of glucagon-like peptide (GLP-1) prescription drugs approved by the FDA for obesity or diabetes treatment. Once approved, the commissioner can contract with manufacturers of these generic drugs and potentially collaborate with other states to supply them. The bill also creates a six-member advisory committee composed of patient advocates, pharmacists, and medical professionals to study ways to maximize access to cost-effective obesity prescription drugs and make recommendations to the Commissioner of Social Services. The committee will review the commissioner's strategic plan and submit recommendations by January 31, 2026, after which the committee will be dissolved. The goal is to help reduce medication costs for the state's Medicaid program while ensuring patients have access to effective obesity treatments.

Health and Social Services

Human Services Committee (J)

https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=SB01421&which_year=2025